Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
William Beaumont Hospital-Royal Oak
mi
from
Royal Oak, MI
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
William Beaumont Hospital-Royal Oak
mi
from
Royal Oak, MI
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Washington University
mi
from
St. Louis, MO
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
St. John's Pediatrics
mi
from
Leavenworth, KA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
St. John's Pediatrics
mi
from
Leavenworth, KA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Stony Brook University Hospital and Medical Center
mi
from
Stony Brook, NY
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Stony Brook University Hospital and Medical Center
mi
from
Stony Brook, NY
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Metro Health Medical Center
mi
from
Cleveland, OH
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
mi
from
Cleveland, OH
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
The Cleveland Clinic
mi
from
Cleveland, OH
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
The Cleveland Clinic
mi
from
Cleveland, OH
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Vanderbilt University Medical Center
mi
from
Nashville, TN
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Louisville, KY
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Louisville, KY
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Ellsworth, ME
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ellsworth, ME
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Omaha, NE
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Omaha, NE
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Providence, RI
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Providence, RI
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Insulin Resistance in Pulmonary Arterial Hypertension
The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Insulin Resistance in Pulmonary Arterial Hypertension
The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Flavanol-Rich Cocoa and Cerebral Blood Flow
Flavanol-Rich Cocoa, Vascular Responses and Mechanisms
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Flavanol-Rich Cocoa and Cerebral Blood Flow
Flavanol-Rich Cocoa, Vascular Responses and Mechanisms
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Mechanism and Treatment of Intradialytic Hypertension
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Mechanism and Treatment of Intradialytic Hypertension
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Mechanism and Treatment of Intradialytic Hypertension
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Status: Archived
UTSW Oakcliff Davita Dialysis
mi
from
Dallas, TX
Mechanism and Treatment of Intradialytic Hypertension
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Status: Archived
Updated: 1/1/1970
UTSW Oakcliff Davita Dialysis
mi
from
Dallas, TX
Mechanism and Treatment of Intradialytic Hypertension
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Status: Archived
UTSW Dallas East Davita Dialysis (Buckner unit)
mi
from
Dallas, TX
Mechanism and Treatment of Intradialytic Hypertension
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Status: Archived
Updated: 1/1/1970
UTSW Dallas East Davita Dialysis (Buckner unit)
mi
from
Dallas, TX
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of South Alabama
mi
from
Mobile, AL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of South Alabama
mi
from
Mobile, AL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Arizona Pulmonary Specialists, Ltd.
mi
from
Phoenix, AZ
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Arizona Pulmonary Specialists, Ltd.
mi
from
Phoenix, AZ
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of California San Diego Medical Center
mi
from
San Diego, CA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of California San Diego Medical Center
mi
from
San Diego, CA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
UCLA Medical Center
mi
from
Los Angeles, CA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
UCLA Medical Center
mi
from
Los Angeles, CA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Children's Hospital of Denver
mi
from
Denver, CO
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Children's Hospital of Denver
mi
from
Denver, CO
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Connecticut Health Center
mi
from
Farmington, CT
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Connecticut Health Center
mi
from
Farmington, CT
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Cleveland Clinic
mi
from
Weston, FL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Cleveland Clinic
mi
from
Weston, FL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Emory University
mi
from
Atlanta, GA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Med College of Georgia
mi
from
Augusta, GA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Med College of Georgia
mi
from
Augusta, GA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Chicago
mi
from
Chicago, IL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Iowa
mi
from
Iowa City, IA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Iowa
mi
from
Iowa City, IA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Louisiana State University
mi
from
New Orleans, LA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Louisiana State University
mi
from
New Orleans, LA